Skip to main content

Advertisement

SpringerLink
Log in

Mechanisms of resistance to trastuzumab: an updated review

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Human epidermal growth factor receptor 2 (HER2) is over-expressed in 20%–25% of invasive breast cancer and is associated with an aggressive tumor phenotype and reduced survival rate. As a clinically widely applied HER2-targeted monoclonal antibody, trastuzumab (Herceptin®), combined with chemotherapy significantly increases the no tumor survival time of the patient. However, the majority of the cancers that initially respond to Herceptin begin to counter against the treatment within 1 year. This review describes several important well-known trastuzumab resistance mechanisms as well as the updated advancement in this field. The sufficiently investigated mechanisms are over-activation of PI3K/AKT pathway, activation of PI3K/AKT via alternative pathway, steric hindrance of receptor-antibody interaction, increase of serum HER2 extracellular domain, and abnormal expression of epidermal growth factor receptor (EGFR) family and their ligands. And the newly investigated mechanisms involve Darpp-32 and t-Darpp, autophagy of tumor cells, HSP27, HSP90, c-MYC, ADAM proteases, EphA2, Rac1, MUC1*, HER2Δ16, and mesenchymal CD44(pos)CD24(neg/low) phenotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wu ZY, Zheng W. Expression of EGFR, C-erbB-2 proteins in breast cancer and their relation with micrometastasis in bone marrow. Chinese-German J Oncol, 2003, 2: 95–98.

    Article  Google Scholar 

  2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002, 20: 719–726.

    Article  CAS  PubMed  Google Scholar 

  3. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 2000, 6: 443–446.

    Article  CAS  PubMed  Google Scholar 

  4. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 2001, 61: 4744–4749.

    CAS  PubMed  Google Scholar 

  5. Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/ neu predicts response and progression-free survival to trastuzumabbased treatment in patients with metastatic breast cancer. Clin Cancer Res, 2004, 10: 1618–1624.

    Article  PubMed  Google Scholar 

  6. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol, 2005, 16: 234–239.

    Article  CAS  PubMed  Google Scholar 

  7. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6: 117–127.

    Article  CAS  PubMed  Google Scholar 

  8. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol, 2000, 20: 3210–3223.

    Article  CAS  PubMed  Google Scholar 

  9. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 2002, 416: 279–280.

    Article  CAS  PubMed  Google Scholar 

  10. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/ HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell, 2009, 15: 429–440.

    Article  CAS  PubMed  Google Scholar 

  11. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 2005, 65: 2554–2559.

    Article  CAS  PubMed  Google Scholar 

  12. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res, 2005, 65: 10992–11000.

    Article  CAS  PubMed  Google Scholar 

  13. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 2007, 12: 395–402.

    Article  CAS  PubMed  Google Scholar 

  14. Lu YH, Zi XL, Zhao YH, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst, 2001, 93: 1852–1857.

    Article  CAS  PubMed  Google Scholar 

  15. Köstler WJ, Hudelist G, Rabitsch W, et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol, 2006, 132: 9–18.

    Article  PubMed  Google Scholar 

  16. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer, 2002, 99: 783–791.

    Article  CAS  PubMed  Google Scholar 

  17. Nagy P, Friedländer E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res, 2005, 65: 473–482.

    CAS  PubMed  Google Scholar 

  18. Bussolati G, Montemurro F, Righi L, et al. A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer, 2005, 92: 1261–1267.

    Article  CAS  PubMed  Google Scholar 

  19. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res, 1998, 58: 5123–5129.

    CAS  PubMed  Google Scholar 

  20. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer, 2008, 113: 1294–1301.

    Article  CAS  PubMed  Google Scholar 

  21. Narayan M, Wilken JA, Harris LN, et al. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res, 2009, 69: 2191–2194.

    Article  CAS  PubMed  Google Scholar 

  22. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 2006, 66: 1630–1639.

    Article  CAS  PubMed  Google Scholar 

  23. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res, 2007, 13: 4909–4919.

    Article  CAS  PubMed  Google Scholar 

  24. Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat, 2005, 91: 187–201.

    Article  CAS  PubMed  Google Scholar 

  25. Gu L, Waliany S, Kane SE. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One, 2009, 4: e6220.

    Article  PubMed  Google Scholar 

  26. Hamel S, Bouchard A, Ferrario C, et al. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat, 2010, 120: 47–57.

    Article  CAS  PubMed  Google Scholar 

  27. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One, 2009, 4: e6251.

    Article  PubMed  Google Scholar 

  28. Kang SH, Kang KW, Kim KH, et al. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer, 2008, 8: 286.

    Article  PubMed  Google Scholar 

  29. Leow CC, Chesebrough J, Coffman KT, et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther, 2009, 8: 2131–2141.

    Article  CAS  PubMed  Google Scholar 

  30. Sahin O, Fröhlich H, Löbke C, et al. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol, 2009, 3: 1–20.

    Article  PubMed  Google Scholar 

  31. Park K, Kwak K, Kim J, et al. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol, 2005, 36: 634–639.

    Article  CAS  PubMed  Google Scholar 

  32. Carr JR, Park HJ, Wang Z, et al. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res, 2010, 70: 5054–5063.

    Article  CAS  PubMed  Google Scholar 

  33. Liu PC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther, 2006, 5: 657–664.

    Article  CAS  PubMed  Google Scholar 

  34. Gijsen M, King P, Perera T, et al. Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer. Breast Cancer Res, 2010, 12: O2.

    PubMed  Google Scholar 

  35. Zhuang G, Brantley-Sieders DM, Vaught D, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res, 2010, 70: 299–308.

    Article  CAS  PubMed  Google Scholar 

  36. Dokmanovic M, Hirsch DS, Shen Y, et al. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther, 2009, 8: 1557–1569.

    Article  CAS  PubMed  Google Scholar 

  37. Fessler SP, Wotkowicz MT, Mahanta SK, et al. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat, 2009, 118: 113–124.

    Article  CAS  PubMed  Google Scholar 

  38. Mitra D, Brumlik MJ, Okamgba SU, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther, 2009, 8: 2152–2162.

    Article  CAS  PubMed  Google Scholar 

  39. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun, 2010, 397: 27–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

    Yan Zhang & Jinsheng Zhang

Authors
  1. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinsheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinsheng Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Y., Zhang, J. Mechanisms of resistance to trastuzumab: an updated review. Chin. -Ger. J. Clin. Oncol. 9, 660–665 (2010). https://doi.org/10.1007/s10330-010-0700-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-010-0700-8

Key words

Search

Navigation